JAMA (Journal of the American Medical Association)
All the latest articles published on JAMA before going in to print Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
نمایش بیشتر📈 تحلیل کانال تلگرام JAMA (Journal of the American Medical Association)
کانال JAMA (Journal of the American Medical Association) (@jamaupdates) در بخش زبانی انگلیسی بازیگری فعال است. در حال حاضر جامعه شامل 17 069 مشترک است و جایگاه 1 455 را در دسته پزشکی و رتبه 2 173 را در منطقه الولايات المتحدة الأمريكية دارد.
📊 شاخصهای مخاطب و پویایی
از زمان ایجاد در невідомо، پروژه رشد سریعی داشته و 17 069 مشترک جذب کرده است.
بر اساس آخرین دادهها در تاریخ 16 نوامبر, 2026، کانال فعالیت پایداری دارد. در ۳۰ روز گذشته تغییر اعضا برابر 371 و در ۲۴ ساعت گذشته برابر 13 بوده و همچنان دسترسی گستردهای حفظ شده است.
- وضعیت تأیید: تأیید نشده
- نرخ تعامل (ER): میانگین تعامل مخاطب 4.24% است و در ۲۴ ساعت نخست پس از انتشار، محتوا معمولاً 1.89% واکنش نسبت به کل مشترکان کسب میکند.
- دسترسی پستها: هر پست به طور میانگین 723 بازدید دریافت میکند. در اولین روز معمولاً 323 بازدید جمعآوری میشود.
- واکنشها و تعامل: مخاطبان بهطور فعال حمایت میکنند؛ میانگین واکنش به هر پست 1 است.
- علایق موضوعی: محتوا بر موضوعات کلیدی مانند patient, disease, treatment, drug, guideline تمرکز دارد.
📝 توضیح و سیاست محتوایی
نویسنده این فضا را محل بیان دیدگاههای شخصی توصیف میکند:
“All the latest articles published on JAMA before going in to print
Discussion Group
https://t.me/Medical_Professionals_Forum
Contact us
https://t.me/Contact_Updates_in_Medicine_Bot”
به لطف بهروزرسانیهای پرتکرار (آخرین داده در تاریخ 17 نوامبر, 2026)، کانال همواره بهروز و دارای دسترسی بالاست. تحلیلها نشان میدهد مخاطبان بهطور فعال با محتوا تعامل دارند و آن را به نقطه اثرگذاری مهم در دسته پزشکی تبدیل کردهاند.
در حال بارگذاری دادهها
| تاریخ | رشد مشترکین | اشارات | کانالها | |
| 17 نوامبر | +1 | |||
| 16 نوامبر | +14 | |||
| 15 نوامبر | +19 | |||
| 14 نوامبر | +10 | |||
| 13 نوامبر | +15 | |||
| 12 نوامبر | +5 | |||
| 11 نوامبر | +17 | |||
| 10 نوامبر | +21 | |||
| 09 نوامبر | +4 | |||
| 08 نوامبر | +12 | |||
| 07 نوامبر | +23 | |||
| 06 نوامبر | +2 | |||
| 05 نوامبر | +17 | |||
| 04 نوامبر | +17 | |||
| 03 نوامبر | +22 | |||
| 02 نوامبر | +76 | |||
| 01 نوامبر | +8 |
| 2 | Alcohol Consumption During Pregnancy in the US—Reply
https://jamanetwork.com/journals/jama/fullarticle/2856800
In Reply We thank Dr Fan and colleagues for their thoughtful letter and for engaging with our study, which reported an increasing trend in alcohol consumption during pregnancy in the US over the past 2 decades. As discussed by the authors, our descriptive results indicate that older maternal age and tobacco use were both notable correlates of any alcohol use, raising questions about overlapping exposure patterns and potential synergistic effects. While our study was designed to assess population-level trends and does not address etiologic aims directly, we are encouraged that the findings have raised other substantive research questions that could have important implications for prevention and practice. | 248 |
| 3 | Alcohol Consumption During Pregnancy in the US
https://jamanetwork.com/journals/jama/fullarticle/2856801
To the Editor The Research Letter by Dr Bruzelius and colleagues documents increased prevalence of alcohol use among pregnant women in the US from 2011 to 2024, particularly among those with older maternal age (35-49 years; 18.2%) and tobacco use (26.3%). Among pregnant women reporting any alcohol use, 68.1% of those who used tobacco also reported binge or heavy drinking, compared with 31.3% of people who did not use tobacco, suggesting a particularly high-risk subgroup that warrants further investigation. | 207 |
| 4 | GLP-1 Utilization After Withdrawal of Medicaid Coverage for Weight Loss
https://jamanetwork.com/journals/jama/fullarticle/2856802
This cross-sectional study uses data from Medicaid State Drug Utilization Data to examine associations of coverage withdrawal with Medicaid beneficiaries’ utilization of weight loss–approved glucagon-like peptide-1s. | 163 |
| 5 | Absolute Risk of Progression to Cognitive Impairment Based on Plasma p-Tau217, Age, Sex, and APOE ε4
https://jamanetwork.com/journals/jamaneurology/fullarticle/2856722
This cohort study examines data from the Mayo Clinic Study of Aging and Alzheimer’s Disease Neuroimaging Initiative to determine the 5- and 10-year absolute risks of mild cognitive impairment and dementia among individuals who are biomarker positive and cognitively unimpaired. | 174 |
| 6 | Agent Orange Exposure and Parkinson Disease Among US Veterans
https://jamanetwork.com/journals/jamaneurology/fullarticle/2856723
This cohort study investigates the association between Agent Orange and risk of incident Parkinson disease diagnosis among US veterans. | 167 |
| 7 | Nationwide Geographic Access to Subcutaneous Anti-Amyloid Alzheimer Disease Therapy Infrastructure
https://jamanetwork.com/journals/jamaneurology/fullarticle/2856724
This cross-sectional study describes how geographic availability of the minimum health care infrastructure required for subcutaneous therapy for Alzheimer disease treatment varies by age and location across the US. | 169 |
| 8 | Intraocular Hemorrhage After Digital Subtraction Myelography
https://jamanetwork.com/journals/jamaneurology/fullarticle/2856725
This case report describes a young adult patient with intraretinal hemorrhages in both eyes resulting in reduction of visual acuity in the left eye. | 155 |
| 9 | Agent Orange and Parkinson Disease—The War Ended, the Exposure Did Not
https://jamanetwork.com/journals/jamaneurology/fullarticle/2856726
Agent Orange was a defoliant widely used by the US during the Vietnam War to uncover the positions of North Vietnamese soldiers. The weed killer was a 50:50 mixture of the herbicides 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T) along with small amounts of a potent carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a by-product of the manufacturing process. From 1962 to 1971, the US sprayed at least 75 million liters (20 million gallons) of defoliants over Vietnam and more over Cambodia, Laos, Thailand, South Korea, and possibly Guam, Panama, and even around military bases in the US. | 160 |
| 10 | HEPA Filtration in Care Homes—Distinguishing Implementation From Intervention Failure
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856318
To the Editor Hay et al should be commended for conducting one of the first large pragmatic trials addressing an important and clinically relevant infection-prevention strategy in a highly vulnerable population. However, I believe that several aspects of this study warrant further consideration. | 230 |
| 11 | Evaluation of Identified Serious Risks for Drugs and Biologics Using Surveillance Systems
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856319
This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025. | 252 |
| 12 | Value Judgments in Comparing Dialysis Facility Performance
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2856321
In 2025, the Centers for Medicare & Medicaid Services (CMS) stopped collecting information about race and ethnicity in the dialysis quality measurement system. Koukounas and colleagues in this issue of JAMA Internal Medicine consider how this change might impact comparisons among dialysis facilities. Using national data, they estimated standardized mortality ratios (SMRs) for these facilities, contrasting the results from risk-adjustment models that either include or exclude race and ethnicity. They find that dialysis facilities that serve more socially disadvantaged patients have better SMRs when the model does not adjust for race and ethnicity. | 272 |
| 13 | Pediatric Obesity Pharmacotherapy
https://jamanetwork.com/journals/jama/fullarticle/2856798
In the current issue of JAMA, Dr Kelly and colleagues present results from SURMOUNT-ADOLESCENTS, a clinical trial of tirzepatide among adolescents with obesity. The results are impressive: mean body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) decreased by 18.5% with tirzepatide compared with a 0.5% increase with placebo, a treatment difference of 19 percentage points at 72 weeks. Nearly half of tirzepatide-treated participants achieved a BMI reduction of at least 20%, and 53.5% of tirzepatide-treated participants achieved a BMI below the 95th percentile at week 72, compared with 7.1% receiving placebo. As evidence supporting antiobesity medications continues to mount, the question is increasingly not whether pharmacotherapy has a role in pediatric obesity treatment, but which medications should be used for which patients and under what circumstances. | 425 |
| 14 | FDA Approves Novel Treatment for Chronic Hepatitis B
https://jamanetwork.com/journals/jama/fullarticle/2856883
The US Food and Drug Administration (FDA) approved bepirovirsen, marketed as Hibsago, in combination with existing antiviral therapy for adults without cirrhosis who have chronic hepatitis B virus (HBV) infection. | 753 |
| 15 | Updated Guidance Released for Type 2 Diabetes Care
https://jamanetwork.com/journals/jama/fullarticle/2856884
The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) released a joint consensus statement offering updated clinical guidance for type 2 diabetes. | 716 |
| 16 | Personalized mRNA Cancer Vaccine Reduces Melanoma Recurrence Risk
https://jamanetwork.com/journals/jama/fullarticle/2856885
A personalized messenger RNA (mRNA) cancer vaccine significantly lowered the risk of disease recurrence or death in patients with high-risk melanoma, a phase 3 trial found. | 708 |
| 17 | Why Do COVID-19 Shots Trigger a Fever for Some?
https://jamanetwork.com/journals/jama/fullarticle/2856877
This Medical News article discusses a study that linked the gut microbiome to fever after COVID-19 vaccination. | 660 |
| 18 | Salt Substitutes Come to the Table
https://jamanetwork.com/journals/jama/fullarticle/2856876
This Medical News article discusses efforts to increase the use of potassium-enriched salt substitutes to lower sodium intake and prevent and manage hypertension. | 601 |
| 19 | JAMA Editors' Summary Podcast November 13, 2026
https://jamanetwork.com/journals/jama/fullarticle/2856887
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA. | 570 |
| 20 | US Health Insurance Coverage Declines
https://jamanetwork.com/journals/jama/fullarticle/2856886
US health insurance coverage and access are in decline after 15 years of expansion, according to a 2026 survey from the Commonwealth Fund. | 538 |
